# The Relationships between Common Measures of Glucose Meter Performance 

Daniel R. Wilmoth, Ph.D.


#### Abstract

Background: Glucose meter performance is commonly measured in several different ways, including the relative bias and coefficient of variation (CV), the total error, the mean absolute relative deviation (MARD), and the size of the interval around the reference value that would be necessary to contain a meter measurement at a specified probability. This fourth measure is commonly expressed as a proportion of the reference value and will be referred to as the necessary relative deviation. A deeper understanding of the relationships between these measures may aid health care providers, patients, and regulators in comparing meter performances when different measures are used.


## Methods:

The relationships between common measures of glucose meter performance were derived mathematically.

## Results:

Equations are presented for calculating the total error, MARD, and necessary relative deviation using the reference value, relative bias, and CV when glucose meter measurements are normally distributed. When measurements are also unbiased, the CV, total error, MARD, and necessary relative deviation are linearly related and are therefore equivalent measures of meter performance.

## Conclusions:

The relative bias and CV provide more information about meter performance than the other measures considered but may be difficult for some audiences to interpret. Reporting meter performance in multiple ways may facilitate the informed selection of blood glucose meters.

J Diabetes Sci Technol 2012;6(5):1087-1093

[^0]
[^0]:    Author Affiliation: U.S. Food and Drug Administration, Silver Spring, Maryland
    Abbreviations: (CV) coefficient of variation, (MARD) mean absolute relative deviation
    Keywords: bias, coefficient of variation, glucose meter, mean absolute relative deviation, performance standard, total error
    Corresponding Author: Daniel R. Wilmoth, Ph.D., U.S. Food and Drug Administration,10903 New Hampshire Ave., WO 32-3261, Silver Spring, MD 20993; email address daniel.wilmoth@fda.hhs.gov

